Neurosterix has raised $105M in Series B funding to advance its lead clinical-stage program, NTX-253, into Phase 2 development for schizophrenia and support research across its broader pipeline of selective allosteric modulators.
The financing was led by RTW Investments, with participation from Janus Henderson Investors, GV, Ikarian Capital, Affinity Asset Advisors, Dellora Investments, Perceptive Advisors and Acorn Bioventures. Neurosterix is based in Geneva, Switzerland, and Boston, Massachusetts.
Funding will support clinical development
Neurosterix said the new capital will be directed first toward the next stage of development for NTX-253. The company describes the program as an oral muscarinic M4 positive allosteric modulator, or PAM, intended to fine-tune neural signaling pathways implicated in schizophrenia.
Moving NTX-253 into Phase 2 would take the program into a later stage of clinical development than its current clinical-stage status. The company did not disclose a financing valuation, the size of the planned Phase 2 trial or a timetable for starting the study in the funding announcement.
A broader central nervous system pipeline
Neurosterix is developing selective allosteric modulators for neuropsychiatric disorders, including schizophrenia, mood disorders and anxiety disorders. Its pipeline includes three named programs:
- NTX-253: an oral muscarinic M4 PAM and the company’s lead clinical-stage program;
- NTX-819: an mGlu7 negative allosteric modulator, or NAM; and
- NTX-529: a second M4 PAM.
The company said its discovery work is supported by a proprietary library of more than 80,000 compounds and over 200 functional assays relevant to the central nervous system. The platform is intended to help Neurosterix identify compounds that adjust neural signaling through allosteric mechanisms rather than by directly activating or blocking the primary binding site.
Company leadership and next stage
Neurosterix is led by CEO Fred Callori. The Series B gives the company capital to pursue the clinical progression of NTX-253 while continuing work on NTX-819, NTX-529 and the underlying compound library.
The financing comes as biotechnology companies continue to use private funding to move programs through clinical development, where costs and timelines typically increase as studies expand. For Neurosterix, the stated near-term objective is specific: fund NTX-253’s transition into Phase 2 development for schizophrenia and maintain development of additional selective allosteric modulators for neuropsychiatric conditions.